Community-based statins and advanced carotid plaque: Role of CD163 positive macrophages in lipoprotein-associated phospholipase A2 activity in atherosclerotic plaque.

[1]  Solid-Timi Investigators.  Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. , 2014 .

[2]  G. Marathe,et al.  To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolase , 2014, Journal of Lipid Research.

[3]  Paul M Ridker,et al.  Anti-inflammatory therapies for cardiovascular disease. , 2014, European heart journal.

[4]  P. Pais,et al.  Darapladib for preventing ischemic events in stable coronary heart disease. , 2014, The New England journal of medicine.

[5]  Dylan L. Steen,et al.  Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. , 2014, JAMA.

[6]  E. Liberopoulos,et al.  Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. , 2013, Atherosclerosis.

[7]  Pina C. Sanelli,et al.  Carotid Plaque MRI and Stroke Risk: A Systematic Review and Meta-analysis , 2013, Stroke.

[8]  M. Kaste,et al.  Haptoglobin 2 allele associates with unstable carotid plaque and major cardiovascular events. , 2013, Atherosclerosis.

[9]  A. Keech,et al.  Changes in Lipoprotein‐Associated Phospholipase A2 Activity Predict Coronary Events and Partly Account for the Treatment Effect of Pravastatin: Results From the Long‐term Intervention with Pravastatin in Ischemic Disease Study , 2013, Journal of the American Heart Association.

[10]  Fabian Bamberg,et al.  Meta-analysis and systematic review of the predictive value of carotid plaque hemorrhage on cerebrovascular events by magnetic resonance imaging. , 2013, Journal of the American College of Cardiology.

[11]  N. Leitinger,et al.  Phenotypic polarization of macrophages in atherosclerosis. , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[12]  R. Rosenson,et al.  Phospholipase A2 enzymes and the risk of atherosclerosis. , 2012, European heart journal.

[13]  Samin K. Sharma,et al.  Genotype-Dependent Impairment of Hemoglobin Clearance Increases Oxidative and Inflammatory Response in Human Diabetic Atherosclerosis , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[14]  J. Adamski,et al.  Evidence Supporting a Key Role of Lp-PLA2-Generated Lysophosphatidylcholine in Human Atherosclerotic Plaque Inflammation , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[15]  P. Ridker,et al.  Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial. , 2012, Clinical chemistry.

[16]  H. Hakonarson,et al.  Translational studies of lipoprotein-associated phospholipase A₂ in inflammation and atherosclerosis. , 2012, Journal of the American College of Cardiology.

[17]  F. Nicoli,et al.  Circulating lipoprotein-associated phospholipase A2 in high-grade carotid stenosis: a new biomarker for predicting unstable plaque. , 2012, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[18]  R. Virmani,et al.  Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. , 2012, Journal of the American College of Cardiology.

[19]  P. Libby,et al.  New Insights into Plaque Stabilisation by Lipid Lowering , 2012, Drugs.

[20]  Jun-xian Song,et al.  Simvastatin Reduces Lipoprotein-associated Phospholipase A2 in Lipopolysaccharide-stimulated Human Monocyte–derived Macrophages Through Inhibition of the Mevalonate–Geranylgeranyl Pyrophosphate–RhoA-p38 Mitogen-activated Protein Kinase Pathway , 2011, Journal of cardiovascular pharmacology.

[21]  J. Danesh,et al.  Lipoprotein‐associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality , 2010, Journal of internal medicine.

[22]  J. Wouter Jukema,et al.  Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters , 2010, Current medical research and opinion.

[23]  J. Danesh,et al.  Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies , 2010, The Lancet.

[24]  J. Stark,et al.  Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype. , 2009, The American journal of pathology.

[25]  F. Moll,et al.  Carotid Atherosclerotic Plaques Stabilize After Stroke: Insights Into the Natural Process of Atherosclerotic Plaque Stabilization , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[26]  W. Insull.  The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. , 2009, The American journal of medicine.

[27]  Ping Zhang,et al.  Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development , 2008, Nature Medicine.

[28]  Frits Mastik,et al.  Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque , 2008, Circulation.

[29]  H. Björkbacka,et al.  Nanomolar concentrations of lysophosphatidylcholine recruit monocytes and induce pro-inflammatory cytokine production in macrophages. , 2008, Biochemical and biophysical research communications.

[30]  F. Meyer,et al.  Enhanced Expression of Lp-PLA2 and Lysophosphatidylcholine in Symptomatic Carotid Atherosclerotic Plaques , 2008, Stroke.

[31]  Chun Yuan,et al.  Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. , 2008, American heart journal.

[32]  F. Moll,et al.  Gender-associated differences in plaque phenotype of patients undergoing carotid endarterectomy. , 2007, Journal of vascular surgery.

[33]  R. Virmani,et al.  Lipoprotein-Associated Phospholipase A2 Protein Expression in the Natural Progression of Human Coronary Atherosclerosis , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[34]  P J Gallagher,et al.  Histological Assessment of 526 Symptomatic Carotid Plaques in Relation to the Nature and Timing of Ischemic Symptoms: The Oxford Plaque Study , 2006, Circulation.

[35]  M. Sabatine,et al.  Lipoprotein-Associated Phospholipase A2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction) Trial , 2006, Circulation.

[36]  P. Ridker,et al.  The effect of statin therapy on lipoprotein associated phospholipase A2 levels. , 2005, Atherosclerosis.

[37]  A. Zalewski,et al.  Lipoprotein-associated phospholipase A2 as a target of therapy , 2005, Current opinion in lipidology.

[38]  Alen Braut,et al.  Histological Analysis of GFP Expression in Murine Bone , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[39]  W. März,et al.  Platelet-Activating Factor Acetylhydrolase Activity Indicates Angiographic Coronary Artery Disease Independently of Systemic Inflammation and Other Risk Factors: The Ludwigshafen Risk and Cardiovascular Health Study , 2005, Circulation.

[40]  W. Landis,et al.  Analysis of connective tissues by laser capture microdissection and reverse transcriptase-polymerase chain reaction. , 2005, Analytical biochemistry.

[41]  P. Rothwell,et al.  Histological Correlates of Carotid Plaque Surface Morphology on Lumen Contrast Imaging , 2004, Circulation.

[42]  G. Zimmerman,et al.  Molecular characterization of the constitutive expression of the plasma platelet-activating factor acetylhydrolase gene in macrophages. , 2003, The Biochemical journal.

[43]  H. Kruth,et al.  Macrophage Foam Cell Formation with Native Low Density Lipoprotein* , 2002, The Journal of Biological Chemistry.

[44]  J. Goudevenos,et al.  Atorvastatin Preferentially Reduces LDL-Associated Platelet-Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and Type IIB , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[45]  G. Lowe,et al.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.

[46]  M. H.,et al.  LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 AS AN INDEPENDENT PREDICTOR OF CORONARY HEART DISEASE , 2000 .

[47]  T. Häkkinen,et al.  Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[48]  C. Hennekens,et al.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.

[49]  W. Roberts,et al.  Morphometric analysis of the composition of coronary arterial plaques in isolated unstable angina pectoris with pain at rest. , 1990, The American journal of cardiology.